XSpray Pharma AB Cash Flow Conversion Efficiency
XSpray Pharma AB cash flow conversion efficiency. Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has a cash flow conversion efficiency ratio of -0.058x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-36.95 Million ≈ $-3.98 Million USD) by net assets (Skr637.50 Million ≈ $68.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of XSpray Pharma AB (2015–2025)
Cash flow conversion efficiency of XSpray Pharma AB from 2015 to 2025. This chart illustrates how XSpray Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XSpray Pharma AB (XSPRAY) stock price for real-time trading data and today's change.
XSpray Pharma AB Cash Flow Conversion Ratio Explained
XSpray Pharma AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
XSpray Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XSpray Pharma AB ranked by their cash flow conversion efficiency. Also see XSPRAY company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Glomac Bhd
KLSE:5020
|
0.034x |
|
C-Tech United
TWO:3625
|
-0.090x |
|
Tai Roun Products Co Ltd
TW:1220
|
-0.040x |
|
Jia Wei Lifestyle Inc
TW:3557
|
0.048x |
|
Golan Plastic
TA:GLPL
|
0.112x |
|
PT Ingria Pratama Capitalindo Tbk
JK:GRIA
|
0.071x |
|
Hwang-Kum Stee
KO:032560
|
0.014x |
|
NS Co. Ltd
KQ:217820
|
0.071x |
Annual Cash Flow Conversion Efficiency for XSpray Pharma AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of XSpray Pharma AB from 2015 to 2025. Review XSPRAY free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr604.65 Million ≈ $65.07 Million |
Skr-193.16 Million ≈ $-20.79 Million |
-0.319x | +10.48% |
| 2024-12-31 | Skr623.10 Million ≈ $67.06 Million |
Skr-222.37 Million ≈ $-23.93 Million |
-0.357x | -21.74% |
| 2023-12-31 | Skr693.41 Million ≈ $74.62 Million |
Skr-203.28 Million ≈ $-21.88 Million |
-0.293x | -47.94% |
| 2022-12-31 | Skr556.02 Million ≈ $59.84 Million |
Skr-110.18 Million ≈ $-11.86 Million |
-0.198x | -127.22% |
| 2021-12-31 | Skr591.75 Million ≈ $63.68 Million |
Skr-51.61 Million ≈ $-5.55 Million |
-0.087x | -6.31% |
| 2020-12-31 | Skr582.59 Million ≈ $62.70 Million |
Skr-47.79 Million ≈ $-5.14 Million |
-0.082x | +10.46% |
| 2019-12-31 | Skr373.71 Million ≈ $40.22 Million |
Skr-34.24 Million ≈ $-3.68 Million |
-0.092x | -55.76% |
| 2018-12-31 | Skr301.72 Million ≈ $32.47 Million |
Skr-17.75 Million ≈ $-1.91 Million |
-0.059x | +17.07% |
| 2017-12-31 | Skr155.66 Million ≈ $16.75 Million |
Skr-11.04 Million ≈ $-1.19 Million |
-0.071x | -89.00% |
| 2016-12-31 | Skr46.47 Million ≈ $5.00 Million |
Skr-1.74 Million ≈ $-187.68K |
-0.038x | +96.45% |
| 2015-12-31 | Skr12.26 Million ≈ $1.32 Million |
Skr-12.96 Million ≈ $-1.40 Million |
-1.057x | -- |
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more